Actos Comes Out Clear In Second Bladder Cancer Risk Study
This article was originally published in PharmAsia News
A now completed large-scale postmarketing study for Takeda's Actos has concluded that there is no association between the use of the diabetes drug and the risk of bladder cancer, although a previously agreed financial settlement of legal cases will go ahead.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.